Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity
by Christina Black | Jun 19, 2020

PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab
by OmniSeq Staff | May 29, 2018
Follow Us on Twitter
This December, Dr. Sarabjot Pabla joins the speaker lineup for the TIGIT Axis Therapies Digital Summit. His presentation will focus on TIGIT RNA expressions and their impact in precision oncology medicines. Register for the virtual event today: https://bit.ly/3NAKg3S
LABCORP EXPANDS ACCESS TO COMPREHENSIVE GENOMIC TESTING THROUGH NEW LUNG CANCER PROGRAM UTILIZING OmniSeq INSIGHT
https://tinyurl.com/59xf82c6
@OmniSeq
@Labcorp
#oncology
#precisionmedicine